Epstein Secrets

t over the past two years "has earned a national reputation for helping states and counties run risk-limiting audits." Meanwhile, Bloomberg (11/15, Allison, 4.73M) reports Georgia's hand recount "is proceeding rapidly with little change in the results so far, according to lawyers working for...Biden's

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

t over the past two years "has earned a national reputation for helping states and counties run risk-limiting audits." Meanwhile, Bloomberg (11/15, Allison, 4.73M) reports Georgia's hand recount "is proceeding rapidly with little change in the results so far, according to lawyers working for...Biden's

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

t over the past two years "has earned a national reputation for helping states and counties run risk-limiting audits." Meanwhile, Bloomberg (11/15, Allison, 4.73M) reports Georgia's hand recount "is proceeding rapidly with little change in the results so far, according to lawyers working for...Biden's

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying